CA2765602C - N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders - Google Patents

N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders Download PDF

Info

Publication number
CA2765602C
CA2765602C CA2765602A CA2765602A CA2765602C CA 2765602 C CA2765602 C CA 2765602C CA 2765602 A CA2765602 A CA 2765602A CA 2765602 A CA2765602 A CA 2765602A CA 2765602 C CA2765602 C CA 2765602C
Authority
CA
Canada
Prior art keywords
antibody
protofibril
terminal truncated
alzheimer
protofibrils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2765602A
Other languages
English (en)
French (fr)
Other versions
CA2765602A1 (en
Inventor
Paer Gellerfors
Lars Lannfelt
Linda Soederberg
Karin Tegerstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
Bioarctic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic AB filed Critical Bioarctic AB
Publication of CA2765602A1 publication Critical patent/CA2765602A1/en
Application granted granted Critical
Publication of CA2765602C publication Critical patent/CA2765602C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2765602A 2009-06-29 2010-06-29 N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders Active CA2765602C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
US61/221,105 2009-06-29
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2765602A1 CA2765602A1 (en) 2011-01-06
CA2765602C true CA2765602C (en) 2021-05-25

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2765602A Active CA2765602C (en) 2009-06-29 2010-06-29 N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders

Country Status (16)

Country Link
US (2) US20120100129A1 (2)
EP (2) EP3892633A1 (2)
JP (3) JP2012532094A (2)
AU (1) AU2010267640B2 (2)
CA (1) CA2765602C (2)
CY (1) CY1124034T1 (2)
DK (1) DK2448968T3 (2)
ES (1) ES2864049T3 (2)
HR (1) HRP20210611T1 (2)
HU (1) HUE053949T2 (2)
LT (1) LT2448968T (2)
PL (1) PL2448968T3 (2)
PT (1) PT2448968T (2)
SI (1) SI2448968T1 (2)
SM (1) SMT202100237T1 (2)
WO (1) WO2011001366A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
BR112013023211B1 (pt) 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
RU2019102746A (ru) 2016-07-14 2020-08-14 Биоарктик Аб Белок для транспорта в мозг
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
MX2021000778A (es) 2018-07-24 2021-03-31 Eisai R&D Man Co Ltd Metodos de tratamiento y prevencion de la enfermedad de alzheimer.
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
RS66984B1 (sr) 2020-06-26 2025-07-31 Bioarctic Ab Antitela koja vezuju alfa-sinuklein protofibril
EP4367516A1 (en) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
US20240352109A1 (en) 2021-08-30 2024-10-24 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
MX2024009492A (es) 2022-02-02 2024-08-09 Eisai R&D Man Co Ltd Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181).
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ATE283285T1 (de) * 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
EP1309341A2 (en) * 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
KR100891620B1 (ko) * 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
BRPI0513959A (pt) * 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
DK2207568T3 (en) * 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína

Also Published As

Publication number Publication date
US20120100129A1 (en) 2012-04-26
JP6884025B2 (ja) 2021-06-09
HUE053949T2 (hu) 2021-08-30
CY1124034T1 (el) 2022-05-27
EP2448968B1 (en) 2021-01-27
JP2019218362A (ja) 2019-12-26
JP2012532094A (ja) 2012-12-13
SI2448968T1 (sl) 2021-07-30
US20230295283A1 (en) 2023-09-21
JP2017197531A (ja) 2017-11-02
WO2011001366A1 (en) 2011-01-06
HRP20210611T1 (hr) 2021-05-28
CA2765602A1 (en) 2011-01-06
EP2448968A1 (en) 2012-05-09
AU2010267640B2 (en) 2015-03-05
ES2864049T3 (es) 2021-10-13
LT2448968T (lt) 2021-05-10
PL2448968T3 (pl) 2021-09-13
SMT202100237T1 (it) 2021-05-07
EP3892633A1 (en) 2021-10-13
AU2010267640A1 (en) 2012-01-19
DK2448968T3 (da) 2021-04-12
PT2448968T (pt) 2021-04-30

Similar Documents

Publication Publication Date Title
US20230295283A1 (en) N-terminal truncated protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's
KR101591206B1 (ko) 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US20200215209A1 (en) Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders
KR101600095B1 (ko) 모노클로널 항 베타 아밀로이드 항체
CN101883790B (zh) 抗淀粉样蛋白β抗体在眼病中的用途
JP6128535B2 (ja) 抗体及びその利用
JP7204235B2 (ja) 活性型α－シヌクレインに結合する抗体
CN101325972B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
JP2022528459A (ja) 融合構築物及びその使用
HK40057935A (en) Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers
HK40007334A (en) Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synucleinrelated disorders
HK1124532B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150501

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250506

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250506